- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01921491
DHACM vs Other Commercially Available Treatments
November 2, 2020 updated by: MiMedx Group, Inc.
The purpose of this study is to determine whether dehydrated human amnion/chorion membrane (dHACM) is more effective than another commercially available product or conservative measures alone when used to treat diabetic foot ulcers (DFUs).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a prospective, stratified, randomized, controlled, comparative, parallel group, multi-center clinical trial comparing the proportion of ulcers completely healed by use of dehydrated human amnion/chorion membrane (dHACM) placed weekly versus placement of bioengineered skin substitute (BSS) placed weekly, versus standard of care in diabetic patients with a diabetic foot ulcer who have adequate arterial perfusion as defined in section, 2.0 (Patient Eligibility), for wound healing to the affected limb.
Study Type
Interventional
Enrollment (Actual)
105
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Oklahoma
-
Tulsa, Oklahoma, United States, 74135
- St. Johns Outpatient Wound Center
-
-
Virginia
-
Roanoke, Virginia, United States, 24016
- Professional Education and Research Institute, Inc.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients age 18 or older.
- Patient is willing to provide informed consent and is willing to participate in all procedures and follow up evaluations necessary to complete the study.
- Patient's ulcer must be diabetic in origin and larger than 1 cm2. Note: Debridement will be done prior to randomization. Subject's informed consent for participating in this study, must be obtained prior to proceeding with sharp debridement.
- Patients with Type 1 or Type 2 diabetes (criteria for the diagnosis of diabetes mellitus per ADA).
- Ulcer must be present for a minimum of four weeks before enrollment/ randomization, with documented failure of conventional ulcer therapy to heal the wound. A two week run-in period will precede enrollment/ randomization in the trial to document the indolent nature of the wounds selected.
- Additional wounds may be present but not within 3 cm of the study wound.
- Wound must be present anatomically on the foot as defined by beginning below the malleoli of the ankle and be neuropathic in origin.
- Patient's ulcer must exhibit no clinical signs of infection.
- Serum Creatinine less than 3.0mg/dl within last six months.
- HbA1c less than or equal to 12% within last 90 days.
Patient has adequate circulation to the affected extremity, as demonstrated by one of the following within the past 60 days:
- Dorsum transcutaneous oxygen test (TcPO2) with results ≥30mmHg, OR
- ABIs with results of ≥0.7 and ≤1.2, OR
- Doppler arterial waveforms, which are triphasic or biphasic at the ankle of affected leg.
Exclusion Criteria:
- Patients presenting with an ulcer probing to tendon, muscle, capsule or bone (UT Grade IIIA-D). A positive probe-to-bone will be confirmed when bone or joint can be felt with a sterile, ophthalmological probe.
- Patients whose index diabetic foot ulcers are greater than 25 cm2.
- Patients considered not in reasonable metabolic control, confirmed by an HbA1c greater than 12% within previous 90 days.
- Patients whose serum creatinine levels are 3.0mg/dl or greater within the last six months.
- Patients with a known history of poor compliance with medical treatments.
- Patients who have been previously randomized into this study, or are presently participating in another clinical trial.
- Patients who are currently receiving radiation therapy or chemotherapy.
- Patients with known or suspected local skin malignancy to the index diabetic ulcer.
- Patients diagnosed with autoimmune connective tissues diseases.
- Non-revascularizable surgical sites.
- Active infection at site.
- Any pathology that would limit the blood supply and compromise healing.
- Patients that have received a biomedical or topical growth factor for their wound within the previous 30 days.
- Patients who are pregnant or breast feeding.
- Patients who are taking medications that are considered immune system modulators which could affect graft incorporation.
- Known allergy to Gentamicin or Streptomycin, or to bovine collagen.
- Patients with known hypersensitivity to components of any treatment used in the trial.
- Wounds greater than one year in duration without intermittent healing.
- Wounds improving greater than 20% over the first two weeks (run-in period) of the trial using standard of care dressing and camboot.
- Patients taking Cox-2 inhibitors.
- Planned use of Dakin's solution, Mafenide Acetate, Scarlet Red Dressing, Tincoban, Zinc Sulfate, Povidone Iodine solution, Mafenide Acetate, Polymyxin/Nystatin or Chlorhexidine during trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Standard of Care
Surgical debridement of DFU, followed by collagen alginate and gauze dressing application to be changed daily by patient.
Patient will practice Offloading.
Reassessment weekly at office visit.
|
Provision of offloading cast walker or similar sponsor-approved device.
May convert into "instant total contact cast" and/or add felt/foam to supplement offloading.
|
Active Comparator: Other Commercially Available Product
Application of commercially available product with Dressing Application, to be changed weekly following surgical debridement.
Patient will practice Offloading.
If the ulcer has not closed completely, an additional application of commercially available product will be applied weekly at weeks 2-11.
|
Provision of offloading cast walker or similar sponsor-approved device.
May convert into "instant total contact cast" and/or add felt/foam to supplement offloading.
Application of a non-adherent dressing, a moisture retentive dressing, and a multi-layer compression dressing.
|
Experimental: dHACM
Application of dHACM with Dressing Application, to be changed weekly following surgical debridement.
Patient will practice Offloading.
If the ulcer has not closed completely, an additional piece of dHACM will be applied weekly at weeks 2-11.
|
Provision of offloading cast walker or similar sponsor-approved device.
May convert into "instant total contact cast" and/or add felt/foam to supplement offloading.
Application of a non-adherent dressing, a moisture retentive dressing, and a multi-layer compression dressing.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of ulcers achieving 100% epithelialization in the dHACM group vs other commercially available product and control.
Time Frame: 6 weeks
|
Visitrak Wound Measurement System
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients achieving 100% epithelialization in dHACM group vs other commercially available product and control.
Time Frame: 12 weeks
|
Visitrak Wound Measurement System
|
12 weeks
|
Cost effectiveness of each treatment modality.
Time Frame: 12 weeks
|
Cost of product x number of visits
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Charles Zelen, DPM, Professional Education and Research Institute, Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2013
Primary Completion (Actual)
September 1, 2015
Study Completion (Actual)
September 1, 2015
Study Registration Dates
First Submitted
August 9, 2013
First Submitted That Met QC Criteria
August 9, 2013
First Posted (Estimate)
August 13, 2013
Study Record Updates
Last Update Posted (Actual)
November 4, 2020
Last Update Submitted That Met QC Criteria
November 2, 2020
Last Verified
November 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- EFDFU005
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Foot Ulcer
-
University of MinnesotaRecruitingDiabetes Mellitus | Foot Ulcer | Ulcer | Diabetic Foot Ulcer | Foot Ulcer, Diabetic | Ulcer Foot | Ulcer, Leg | Ankle UlcerUnited States
-
Community Pharmacology Services LtdKeneric HealthcareNot yet recruitingDiabetic Foot Ulcer | Diabetic Foot Ulcer Neuropathic | Diabetic Foot Ulcer Ischemic
-
University of PadovaUnknownDiabetic Foot | Diabetic Foot Ulcer | Diabetic Foot Infection | Diabetic Foot Ulcer Neuropathic | Deformities FootItaly
-
Johns Hopkins UniversityWithdrawnDiabetic Foot | Diabetic Foot Ulcer | Diabetic Foot Infection | Diabetic Foot Ulcer Mixed | Vascular Ulcer (Arterial or Venous Including Diabetic Ulcers Not Located on the Foot)
-
Corporacion Parc TauliCompletedDiabetic Foot Ulcer | Diabetic Foot Ulcer NeuropathicPakistan
-
Baylor College of MedicineLifeNet HealthCompletedDiabetic Foot Ulcer | Deep Diabetic Foot UlcerUnited States
-
Exciton Technologies Inc.CompletedDiabetic Foot Ulcer | Diabetic Foot Infection | Non-healing Diabetic Foot UlcerCanada
-
ETS Wound Care, LLCProfessional Education and Research InstituteCompletedDiabetic Foot | Diabetic Foot Ulcer | Ulcer FootUnited States
-
National and Kapodistrian University of AthensTerminatedDiabetic Foot | Chronic Diabetic Foot Ulcer of Right Foot | Neuropathic Foot Ulcer | Chronic Diabetic Ulcer of Left Foot (Diagnosis)Greece
-
University of the PunjabHigher Education Commission (Pakistan); Centre of Excellence in Molecular Biology... and other collaboratorsRecruitingDiabetes Mellitus | Diabetic Foot | Foot Ulcer | Diabetes Complications | Diabetic Foot Ulcer | Diabetic Foot Infection | Diabetic Foot Ulcer Neuropathic | Foot Ulcer Due to Type 1 Diabetes Mellitus | Foot Ulcer Due to Type 2 Diabetes Mellitus | Chronic Diabetic Ulcer of Left Foot | Chronic Diabetic Foot...Pakistan
Clinical Trials on Offloading
-
Lower Extremity Institute for Research and TherapyMusculoskeletal Transplant FoundationUnknownDiabetic Foot | Foot Ulcer; DiabeticUnited States
-
DeRoyal Industries, Inc.Lincoln Memorial UniversityCompletedHeel Pressure Ulceration Prevention StrategiesUnited States
-
Diabetica Solutions Inc.National Institutes of Health (NIH)UnknownDiabetes | Elevated Temperature | Neuropathic Limb | Shear Pressure | Increased TemperaturesUnited States
-
Musculoskeletal Transplant FoundationProfessional Education and Research InstituteCompletedDiabetic; Foot UlcersUnited States
-
Baylor College of MedicineThe Diabetic Boot CompanyCompletedDiabetic Foot Ulcer | OffloadingUnited States
-
Jeffrey A. Gusenoff, MDCompletedHeel Pain Syndrome | Plantar Fasciitis, Chronic | Fat Pad SyndromeUnited States
-
University of PlymouthUniversity Hospital Plymouth NHS TrustUnknownDiabetic | Neuropathic | Past UlcerationUnited Kingdom
-
EmoledUniversity of Pisa; Ospedale San DonatoRecruiting
-
Professional Education and Research InstituteMusculoskeletal Transplant FoundationCompletedDiabetic Foot UlcerUnited States
-
Compedica IncProfessional Education and Research InstituteRecruitingDiabetic Foot UlcerUnited States, Canada